You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
None
Questions and concerns regarding the scope and depth of Canada's relationship with the United States loom larger than ever since 9/11. In Whose Canada?, contributors provide a comprehensive analysis of the legacy of free trade and look at the challenges that deepening bilateral integration presents for Canadian sovereignty and public policy autonomy. They focus on trade and economics, politics, public policy, social policy, labour, health care, education, local government, minority rights, military and security, foreign policy, culture, law, Quebec, environment, energy, and civil society. In response to the question Whose Canada?, the authors share their scepticism about corporate Canadas co...
By exposing the separation of art and labour, Art Work provides a valuable, historical perspective on the present-day struggle for artists' rights.
Is it possible to harness the benefits of economic globalization without sacrificing social equity, ecological sustainability, and democratic governance? The first edition of Civilizing Globalization (2003) explored this question at a time of widespread popular discontent. This fully revised and expanded edition comes at an equally crucial juncture. The period of relative stability and prosperity in the world economy that followed the release of the first edition ended abruptly in 2008 with a worldwide economic crisis that illustrated in dramatic fashion the enduring problems with our global order. Yet despite the gravity of the challenges, concrete initiatives for change remain insubstantial. Richard Sandbrook and Ali Burak Güven bring together international scholars and veteran activists to discuss in clear, nontechnical language the innovative political strategies, participatory institutional frameworks, and feasible regulatory designs capable of taming global markets so that they assume the role of useful servants rather than tyrannical masters.
The British coal industry no longer exists and yet the figure of the coal miner lives on in the British cultural imagination. In feature films and documentaries, miners are typically portrayed as proletarian traditionalists working in a dying industry. Taking this perspective, the 1984/85 miners' strike seems a desperate last stand against forces much bigger than the miners themselves — not just the Thatcher government but the tide of historical change itself. In this ground-breaking study, Jörg Arnold challenges a declinist reading of the people working in one of Britain's most important energy industries. The study makes extensive use of previously inaccessible records to offer a new ac...
A scholarly narrative of The University of Alabama at Birmingham from its nascent beginnings through the mid 1990s.
The Trans-Pacific Partnership, with its twelve participating countries on three continents, is the largest regional trade and investment agreement that Canada has ever negotiated. It is also one of the most controversial— for good reason. Negotiations ended exactly a year ago, in October 2015, and the TPP was signed in New Zealand in February 2016. But there is no guarantee it will ever come into effect. Opposition to the TPP is strongest in the United States, where both 2016 presidential nominees vowed to kill or significantly renegotiate the deal. Outgoing President Barack Obama characterized the TPP as a Made-in-America deal in the hope of getting it passed into law shortly after the No...
Despite the many basic research discoveries in genetics, relatively few gene-based treatments, drugs, or preventative measures have been developed. One way to bridge this gap may be for industry, academia, and government to develop partnerships that share resources while distributing risk. However, intellectual property protections and other barriers can inhibit collaborative efforts. The Institute of Medicine held a workshop on July 22, 2010, to explore these issues and develop solutions.
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cure...